Wednesday, September 09, 2020 1:28:13 PM
Subject: The Future of Amarin Management
Dear Mr. Ekman,
I do not have the email addresses of any other board members and emailing IR is useless since they work for Thero. I know you are probably a very busy man and probably have heard this before but nonetheless after seeing such failure from Amarin's management I feel compelled to speak to someone in a position to do something about Thero and what I and many other shareholders consider the incompetent management of Amarin.
John Thero represents Amarin and Vascepa poorly to wall street and others in the industry. Despite having risen from an accountant to the CEO he has never learned to speak properly. In fact he makes Ben Stein in Ferris Bueller look charismatic. A CEO who can energetically promote the company makes a difference (look at Tesla despite certain accounting irregularities its over 1000 dollars) and Amarin very much needs this right now.
In addition Thero has made a number of very poor decisions. 1st of all he allowed the patent lawsuit to be filed in the 9th circuit court district (Kennedy should be fired for this too as chief legal counsel). Amarin would have almost certainly prevailed in the lawsuit had they gotten a Republican judge who would be more inclined to respect property rights and the letter of the law. This error alone is unforgivable and all who supported this decision should be fired.
Despite angering the FDA with the free speech lawsuit (and I agree with the free speech lawsuit) he has not exploited what he won to market Vascepa aggressively over the counter from the minute the Reduce-IT study was published. Why win that right in court if you are not going to use it. There was nothing legally stopping direct to consumer commercials highlighting the Reduce-IT results. Given that the FDA has approved Hikma's drug there was no point in playing nice with the FDA regarding this point.
Also given how political drug marketing is Thero has spent no money hiring lobbyists... I cannot but feel that if Amarin had some political backing things would have gone better not just with the patent court but with insurance coverage and many other things would have gone better. Most pharma companies spend extensively on lobbying and I think not without good reason.
Thero has also compensated himself very well at shareholder expense despite all this bungling that I cannot consider him anything else but a thief. At the very least management compensation needs to be cut to the bare minimum its my understanding Thero and his fellow crooks are now helping themselves to something like 30 million a year.
Thero appeared to have made one good decision in his very unpopular dilution to raise 400 million dollars BUT its questionable whether this would ever have been needed had the company done the right thing and filed the court case in a district where he would have been almost certain to get a conservative judge.
There is still great value in Vascepa but I do not believe it can be realized with Thero and Kennedy there. I also believe that Wall Street has zero confidence in them. I would greatly appreciate you at the very least responding to me and removing any ambiguity as to whether the board is considering his dismissal and that of Kennedy as well if the board has decided that Thero will stay on no matter what I have no faith in the future of this company.
Recent AMRN News
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:31:21 PM
- Amarin Chairman & CEO Issue Letter to Shareholders • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM